Active	Status	Sponsor type	Region	Phase	Filter
9 Active 0 Inactive 9 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Madroszyk, Anne
ELDERLY, NCT03977194: Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy	Active, not recruiting	3	500	Europe	Carboplatin, Paclitaxel, Atezolizumab	Intergroupe Francophone de Cancerologie Thoracique	Non Small Cell Lung Cancer Metastatic	12/24	12/26
PERSEE, NCT04547504: PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 %	Active, not recruiting	3	349	Europe	Pembrolizumab, Pembrolizumab and Chemotherapy drugs	University Hospital, Brest, Groupe Français de Pneumo-Cancérologie	Non-small-cell Lung Cancer	12/25	12/25
ORBITAL, NCT04233021: Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation	Active, not recruiting	2	57	Europe	Osimertinib	Intergroupe Francophone de Cancerologie Thoracique	Non Small Cell Lung Cancer Metastatic, Leptomeningeal Metastasis, Brain Metastases, EGFR Activating Mutation	03/23	12/24
ORAKLE, NCT04111705: Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients with Advanced ALK-positive Non-small Cell Lung Cancer	Active, not recruiting	2	23	Europe	Lorlatinib	Intergroupe Francophone de Cancerologie Thoracique	Non Small Cell Lung Cancer Metastatic	01/25	01/25
ENCO-BRAF, NCT04526782 / 2019-004621-24: ENCOrafenib with Binimetinib in BRAF NSCLC Jul 2022 - Dec 2022 : Pivotal data readout from ENCO-BRAF trial in combination with Mektovi for NSCLC	Recruiting	2	119	Europe	Encorafenib 75 MG, Binimetinib 15 MG	Intergroupe Francophone de Cancerologie Thoracique, IFCT, Pierre Fabre	Non Small Cell Lung Cancer, BRAF V600E	12/24	03/26
NCT04621188: Lorlatinib After Failure of First-line TKI in Patients with Advanced ROS1-positive NSCLC (ALBATROS)	Recruiting	2	84	Europe	Lorlatinib	Intergroupe Francophone de Cancerologie Thoracique	Non Small Cell Lung Cancer Metastatic	03/25	01/26
IFCT-2101 MASTERPROTOCOL ALK, NCT05200481: Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)	Active, not recruiting	2	110	Europe	Brigatinib 180 MG, ALUNBRIG, Carboplatin, Pemetrexed	Intergroupe Francophone de Cancerologie Thoracique	Non Small Cell Lung Cancer, ALK Gene Mutation	04/25	10/28
ADAPTABLE, NCT05781308: Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients with Advanced NSCLC Progressing After Immunotherapy & Chemotherapy	Active, not recruiting	2	156	Europe	Paclitaxel, Bevacizumab, Avastin, Atezolizumab, Tecentriq	Intergroupe Francophone de Cancerologie Thoracique	Non Small Cell Lung Cancer	09/25	06/26
BIOEXALK, NCT05122806: Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC	Recruiting	N/A	100	Europe	RNAseq, DNA NGS	Groupe Francais De Pneumo-Cancerologie, Takeda	Non-small Cell Lung Cancer, ALK Gene Rearrangement Positive	06/27	06/27